A new study in the New England Journal of Medicine shows promising results for bionic pancreases.
New Study On Bionic Pancreas Shows Efficacy in controlling hemoglobin A1C
A new study in the New England Journal of Medicine finds that a bionic pancreas was more effective in controlling hemoglobin A1C levels compared to standard care. The study was 13 weeks long, included participants from the ages of 6 to 79, and involved 326 participants, 219 of which were randomly assigned to the bionic pancreas group and 107 to the standard care group, which was just to continue managing their diabetes the way they had been.
Among other findings, the study found a reduction in glycated hemoglobin levels for the bionic pancreas group and no such change in the standard care group. This is an important measure for diabetics, as it shows the long term concentration of glucose in their blood by proxy of hemoglobin with a sugar attached to it (hence the “glycated” in glycated hemoglobin).
The study shows promise for bionic pancreases as a new method for insulin delivery, as it reduces user input compared to other methods.